(NASDAQ: TNXP) Tonix Pharmaceuticals Holding's forecast annual revenue growth rate of 204.66% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 49.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 16.72%.
Tonix Pharmaceuticals Holding's revenue in 2026 is $13,107,000.On average, 5 Wall Street analysts forecast TNXP's revenue for 2026 to be $356,878,585, with the lowest TNXP revenue forecast at $315,295,032, and the highest TNXP revenue forecast at $396,933,924. On average, 4 Wall Street analysts forecast TNXP's revenue for 2027 to be $1,599,130,285, with the lowest TNXP revenue forecast at $1,332,121,508, and the highest TNXP revenue forecast at $1,865,093,441.
In 2028, TNXP is forecast to generate $2,933,369,847 in revenue, with the lowest revenue forecast at $1,616,557,307 and the highest revenue forecast at $4,307,155,341.